VanEck Biotech ETF (NASDAQ:BBH) Short Interest Down 67.9% in April

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 2,500 shares, a decrease of 67.9% from the March 31st total of 7,800 shares. Based on an average daily trading volume, of 7,200 shares, the days-to-cover ratio is currently 0.3 days.

VanEck Biotech ETF Stock Down 1.6 %

Shares of BBH traded down $2.56 during trading hours on Thursday, reaching $154.77. 53,720 shares of the company traded hands, compared to its average volume of 9,120. The stock has a fifty day simple moving average of $162.38 and a 200 day simple moving average of $159.79. VanEck Biotech ETF has a fifty-two week low of $142.51 and a fifty-two week high of $171.04.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Altfest L J & Co. Inc. raised its holdings in VanEck Biotech ETF by 4.2% in the 1st quarter. Altfest L J & Co. Inc. now owns 7,895 shares of the company’s stock valued at $1,313,000 after acquiring an additional 319 shares during the last quarter. CIBC Private Wealth Group LLC acquired a new position in VanEck Biotech ETF in the fourth quarter valued at $572,000. Condor Capital Management purchased a new position in VanEck Biotech ETF during the fourth quarter worth about $800,000. Focus Financial Network Inc. ADV acquired a new stake in VanEck Biotech ETF in the 4th quarter worth about $2,328,000. Finally, Pine Valley Investments Ltd Liability Co grew its holdings in VanEck Biotech ETF by 13.2% in the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 2,150 shares of the company’s stock valued at $355,000 after buying an additional 250 shares during the period. 32.05% of the stock is currently owned by hedge funds and other institutional investors.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.